Navigation Links
Dreier LLP Announces Class Action Lawsuit Against Vertex Pharmaceuticals Incorporated (VRTX)
Date:3/20/2008

s C. Among other things, the Complaint alleges that Defendants made positive statements concerning VX-950 and the Company's PROVE 2 trial while simultaneously failing to disclose unfavorable data uncovered during the PROVE 2 trial. On November 2, 2007, before the market closed, the Company disclosed the truth concerning the PROVE 2 trial. As a direct and proximate result of this news, the price of Vertex stock declined $2.74 per share to close at $28.90 per share, a one day decline of 9%, on extremely high trading volume.

Dreier LLP's Class Action Litigation Group has vast experience representing domestic and foreign institutional and individual investors in securities and other class actions throughout the country. The partners who head Dreier LLP's Class Action Litigation Group have successfully prosecuted securities fraud class actions in a wide variety of industries and have played a significant role in cases that have resulted in some of the largest securities class action settlements. Prior results do not guarantee a similar outcome. As of the date of this Notice, Dreier LLP has not filed a Complaint against Vertex.

Background on Dreier LLP

Dreier LLP was founded in 1996 by Marc Dreier as a more responsive and innovative alternative to traditional "large-firm" lawyering. Dreier LLP represents a wide range of institutional, entrepreneurial and individual clients in diverse sectors of financial, industrial and service-oriented markets. The firm's principal practices are commercial litigation, class action litigation, real estate, bankruptcy and corporate reorganization, employment, corporate and securities, entertainment, intellectual property, matrimonial and tax. Dreier LLP's Los Angeles affiliate, Dreier Stein Kahan Browne Woods George LLP, has its principal practice in entertainment and commercial litigation and corporate transactions. The firm's New York affiliate Schlesinger Gannon & Lazetera LLP has an extensive practice in the area o
'/>"/>

SOURCE Dreier LLP
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Blue Cross and Blue Shield of Illinois Announces Wellness Tools and Resources
2. Blue Cross and Blue Shield of Illinois Announces Campaign to Address Childhood Obesity
3. Blue Cross and Blue Shield of Illinois Announces 2007 Charitable Donations
4. IPC The Hospitalist Company Announces Board of Director Member Changes
5. MedCom Announces Court Rules Card Activation Technologies Patent Is Valid
6. Patrick G. Ryan Announces Intention to Retire from Aon
7. Pregis Announces Fouth Quarter and Full Year 2007 Financial Results
8. Takeda Announces New U.S. Leadership
9. QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes
10. Galderma Announces HSR Clearance for Its Proposal to Acquire CollaGenex Pharmaceuticals
11. The Pennsylvania Breast Cancer Coalition Announces Event at the University of Pennsylvania Hospital to Celebrate the 2008 Income Tax Check-Off Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... known as marijuana is broadly believed to ... (MGH) investigators found that 40 percent of cannabis-using ... reported experiencing symptoms of withdrawal, which are considered ... reporting withdrawal were more likely to meet criteria ... although the presence or absence of withdrawal did ...
(Date:9/1/2014)... Building on the success of the ... and Breathing Academy (ASBA) has officially announced its ... Professionals. The event will be taking place at the ... 11th. This years’ event promises to be yet another ... , In recent years, Pro Player Health Alliance ...
(Date:9/1/2014)... HealthDay Reporter SATURDAY, Aug. 30, ... experimental drug was more effective than standard treatment at ... According to the study authors, the trial was stopped ... drug, dubbed LCZ696. In the trial, 26.5 ... either died or were hospitalized due to heart failure, ...
(Date:9/1/2014)... Albany, New York (PRWEB) September 01, 2014 ... specially-fitted room in a hospital for performing surgical operations. ... such as operating tables, surgical booms, operating room lights, ... rooms. According to a report by Transparency Market Research, ... market is expected to reach USD 4.5 billion by ...
(Date:9/1/2014)... 1 September 2014: Daily fruit consumption cuts the risk ... to research presented at ESC Congress today by Dr ... seven year follow-up study of nearly 0.5 million people ... fruit people ate, the more their risk of CVD ... disease (IHD) and stroke, is the leading cause of ...
Breaking Medicine News(10 mins):Health News:Cannabis withdrawal symptoms common among adolescents treated for substance use disorder 2Health News:Cannabis withdrawal symptoms common among adolescents treated for substance use disorder 3Health News:Pro Player Health Alliance Confirms Big Name Speakers at 2015 American Sleep and Breathing Academy Conference 2Health News:Pro Player Health Alliance Confirms Big Name Speakers at 2015 American Sleep and Breathing Academy Conference 3Health News:Pro Player Health Alliance Confirms Big Name Speakers at 2015 American Sleep and Breathing Academy Conference 4Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 2Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 3Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 2Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 3Health News:Fruit consumption cuts CVD risk by up to 40 percent 2Health News:Fruit consumption cuts CVD risk by up to 40 percent 3
... DARIEN, Ill., June 17 Healthation CEO Scott ... Vice President of,Business Development today. Mr. Hebert was ... experience in sales of complex solutions in the ... the sales and,marketing organization and growing market share ...
... PartsSource, the nation,s leading,supplier of replacement medical ... straight "World Class Customer Service" award for Northern,Ohio. ... Promise and,its ability to consistently meet or exceed ... by Smart Business magazine, which further,honored PartsSource,s President ...
... NORTH HOLLYWOOD, Calif., June 17 IPC The,Hospitalist ... national hospitalist,physician group practice, today announced that it ... and Exchange Commission in connection,with a proposed offering ... shares to be registered include 3,889,769 shares owned ...
... extract reduces plaque formation and resulting cognitive impairment in ... The study appears in the June 18 issue of ... study author Giulio Pasinetti, MD, PhD, of Mount Sinai ... seed extract prevents amyloid beta accumulation in cells, suggesting ...
... researchers at Washington University School of Medicine in St. ... the risk of metabolic syndrome, a group of factors ... found appeared to protect against the condition. , People ... following symptoms: abdominal obesity, high blood triglyceride levels, lower ...
... and stress-reduction spur healthy alterations in DNA, study finds, ... not fully control your destiny when it comes to ... with prostate cancer. , New research suggests that stringent ... can change the expression of hundreds of genes. ...
Cached Medicine News:Health News:IPC The Hospitalist Company, Inc. Files Registration Statement for Proposed Offering 2Health News:IPC The Hospitalist Company, Inc. Files Registration Statement for Proposed Offering 3Health News:Study indicates grape seed extract may reduce cognitive decline associated with Alzheimer's disease 2Health News:Study indicates grape seed extract may reduce cognitive decline associated with Alzheimer's disease 3Health News:Gene variants linked to metabolic syndrome and HDL cholesterol levels 2Health News:Gene variants linked to metabolic syndrome and HDL cholesterol levels 3Health News:Lifestyle Changes Affect Cancer Genes 2Health News:Lifestyle Changes Affect Cancer Genes 3
(Date:8/29/2014)... 29, 2014 According to ... by Extraction type (SFE, Cold Pressed, Organic Solvent, & ... Pharmaceutical, Food Supplements, Fragrance, & Others) - Global Trends ... and segments the Amaranth Seed Oil Market with ... in terms of value. The Amaranth Seed Oil ...
(Date:8/29/2014)... 2014  United Therapeutics Corporation (NASDAQ: UTHR ... the District of New Jersey ... against Sandoz, Inc. regarding United Therapeutics, Remodulin ® ... that U.S. Patent No. 6,765,117 is both valid and ... its generic product until the expiration of that patent ...
(Date:8/29/2014)... 29, 2014 Diseases largely eradicated in ... are returning. Measles was declared eliminated in 2000, yet ... of August 15—the highest incidence in 20 years. In ... declared whooping cough a problem of "epidemic proportions." ... and dying from these preventable diseases—in part because some ...
Breaking Medicine Technology:Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4District Court Decision Received In Remodulin Patent Case 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3
... Israel--(BUSINESS WIRE)--Jun 14, 2007 - Can-Fite,BioPharma (TASE:CFBI), a ... Exchange, proceeds with the development of its,third drug ... is currently,in clinical trials and CF102, which is ... the EUALR annual congress of,rheumatology in-vitro and in ...
... of SLE,disease at 52 Weeks and demonstrated ... ROCKVILLE, Md., June 14, 2007 /PRNewswire-FirstCall/ -- ... of Phase 2,trial data demonstrating that LymphoStat-B(R) ... was well tolerated and improved quality of ...
Cached Medicine Technology:Can-Fite Proceeds with Development of Third Drug; Progress in,Development of CF502 Will Be Presented at the Annual European,Congress of Rheumatology 2Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 2Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 3Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 4Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 5Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 6Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 7Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 8